Highly Potent Drug Manufacturing Summit HPAPI on August 13-14, 2025 in Boston, United States

The global demand for highly potent drugs is growing rapidly, with the market projected to reach $46.9B by 2030, driven by innovations in drug delivery technologies, regulatory advancements, and the rising need for personalized treatments. The oncology sector has been a key witness to this, experiencing substantial growth due to the increasing adoption of small molecules, conjugates, and other targeted therapies.

At the forefront of it all, we're thrilled to announce that the 14th Highly Potent Drug Manufacturing Summit is back in August 2025, offering in-depth case studies on the latest innovations in developing cytotoxic compounds, strengthening process collaborations, and safely scaling up manufacturing.

As a free-to-attend* event for drug developers this year in Boston, you'll experience a completely revamped agenda, designed to meet the industry's evolving needs of 90+ Vice Presidents, Directors, and Heads of CMC, Tech Operations, Process Chemistry, Drug Substance and Product, EHS, and Industrial Hygiene.

Whether you'd like to secure the best CDMO, optimize upstream development, or create a work environment conducive to occupational safety, this is the place to be!

Hear from some of our most renowned speakers and network with your forward-thinking peers from the likes of Pfizer, Bristol Myers Squibb, Johnson and Johnson, Biogen, Teva Pharmaceuticals, Relay Therapeutics, and more.

URLs:
Tickets: https://go.evvnt.com/2958544-2?pid=10008
Brochure: https://go.evvnt.com/2958544-3?pid=10008
LinkedIn: https://go.evvnt.com/2958544-4?pid=10008

Time: 8:00 AM - 2:45 PM

Prices:
Drug Developer and Academic Pricing: USD 0.50,
Solution Providers: USD 3699.00

Speakers: Thomas Fenton, Senior Specialist, EHS, Alkermes, Omid ZadakBar, Senior Manager, Global EHS Design Engineering, Amgen, Linda Jackowiak, Associate Director, EHS, Chemical Safety and Industrial Hygiene, AstraZeneca, Thomas Adam, Head, Global Quality Assurance, Chemical API, Bayer, Suzie Opalka, Associate Director, Chemical Process Development, Biogen, Tae Correia, Associate Scientist, Technical Development, Biogen, Ronald Amoling, Associate Director, EHS, Bristol Myers Squibb, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences, Bernard Shamsai, Executive Director, Process Development, Gilead Sciences, Rupesh Nanjunda, Associate Director, Biologics Drug Product Development, Johnson and Johnson, David Cragin, Senior Director, Product Science, EHS and Sustainability, Teva Pharmaceuticals, Talia Planas-Fontanez, Senior Occupational Toxicologist, EHS and Sustainability, Teva Pharmaceuticals, Naiffer Romero, Principal Scientist, Scientific Affairs, US Pharmacopeia, Mark Witcher, Subject Matter Expert, Biopharma Operations, Independent, Srinath Thirumalairajan, Director, Process Engineering, Small Molecules, Pfizer, Surendra Singh, Vice President, Drug Substance Development and Manufacturing, CMC, Relay Therapeutics